Overview

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer